Henryschein Dental Company (HSIC)

Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services sector, raising doubts about near-term rate cuts and weighing on risk appetite.

Henry Schein affirms 2025 EPS outlook and projects 2%–4% sales growth, recording $25 million in restructuring costs in Q1 2025.

Dental and medical products company Henry Schein (NASDAQ:HSIC) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $3.17 billion. Its non-GAAP profit of $1.15 per share was 3.6% above analysts’ consensus estimates.

U.S. stock futures fell on Monday after a nine-day winning streak on the S&P 500 index. Futures of benchmark indices were lower in premarket.

Dental and medical products company Henry Schein (NASDAQ:HSIC) will be announcing earnings results tomorrow before the bell. Here’s what investors should know.

Let’s dig into the relative performance of Dentsply Sirona (NASDAQ:XRAY) and its peers as we unravel the now-completed Q4 dental equipment & technology earnings season.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Envista (NYSE:NVST) and the best and worst performers in the dental equipment & technology industry.

Since September 2024, Henry Schein has been in a holding pattern, floating around $72.51.

Let’s dig into the relative performance of Align Technology (NASDAQ:ALGN) and its peers as we unravel the now-completed Q4 dental equipment & technology earnings season.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Henry Schein (NASDAQ:HSIC) and the best and worst performers in the dental equipment & technology industry.

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Wednesday.

Dental and medical products company Henry Schein (NASDAQ:HSIC) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 5.8% year on year to $3.19 billion. Its non-GAAP profit of $1.19 per share was 1.6% below analysts’ consensus estimates.

Henry Schein Q4 sales grew 5.8% to $3.19 billion, missing estimates. The company was restructured into three segments.

Dental and Medical products company Henry Schein (NASDAQ:HSIC) will be reporting results tomorrow morning. Here’s what investors should know.

Henry Schein has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.3% to $77.62 per share while the index has gained 12.2%.